Moreover, in patients with T2D and established HF with reduced ejection fraction (HFrEF), an SGLT-2 inhibitor with proven benefit in this patient population is recommended to reduce the risk of worsening HF and CV death. Here, SLC5A2 is linked to hydrops fetalis.